Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AlphaTON Capital ( (ATON) ) has shared an announcement.
On November 25, 2025, AlphaTON Capital Corp announced the filing of a prospectus supplement with the SEC for the sale of up to $15,307,818 of its ordinary shares under an At-The-Market Offering Agreement with Chardan Capital Markets. This move is part of a strategic effort to raise capital through flexible market transactions, potentially impacting the company’s financial operations and market presence.
Spark’s Take on ATON Stock
According to Spark, TipRanks’ AI Analyst, ATON is a Neutral.
Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock’s attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.
To see Spark’s full report on ATON stock, click here.
More about AlphaTON Capital
AlphaTON Capital Corp, formerly known as Portage Biotech, Inc., operates in the financial sector and is involved in capital markets. The company is focused on offering and selling ordinary shares through market transactions, primarily targeting the Nasdaq Capital Market and other trading markets in the United States.
Average Trading Volume: 1,292,468
Technical Sentiment Signal: Sell
Current Market Cap: $17.4M
See more data about ATON stock on TipRanks’ Stock Analysis page.